Primary Site >> Colorectal Cancer

Gene >> UGT1A1

1.
Journal: Carcinogenesis. 1999 Jun;20(6):1107-14.
Title: Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5-b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved.
Author: Nowell, S A|Massengill, J S|Williams, S|Radominska-Pandya, A|Tephly, T R|Cheng, Z|Strassburg, C P|Tukey, R H|MacLeod, S L|Lang, N P|Kadlubar, F F
PMID: 10357796
2.
Journal: Cancer Res. 1999 Dec 1;59(23):5938-46.
Title: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
Author: Brangi, M|Litman, T|Ciotti, M|Nishiyama, K|Kohlhagen, G|Takimoto, C|Robey, R|Pommier, Y|Fojo, T|Bates, S E
PMID: 10606239
3.
Journal: Ther Drug Monit. 2000 Feb;22(1):10-3.
Title: Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid.
Author: Mackenzie, P I
PMID: 10688250
4.
Journal: Mol Carcinog. 2000 Dec;29(4):198-204.
Title: Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer?
Author: Grant, D J|Bell, D A
PMID: 11170257
5.
Journal: Curr Oncol Rep. 2001 Mar;3(2):102-8.
Title: Determinants of prognosis and response to therapy in colorectal cancer.
Author: Iqbal, S|Lenz, H J
PMID: 11177741
6.
Journal: Gut. 2002 Jun;50(6):748-9.
Title: UGT1A1 polymorphisms and colorectal cancer susceptibility.
Author: Brockton, N T
PMID: 12010871
7.
Journal: Drug Metab Dispos. 2003 Apr;31(4):452-61.
Title: Glucuronides of tea catechins: enzymology of biosynthesis and biological activities.
Author: Lu, Hong|Meng, Xiaofeng|Li, Chuan|Sang, Shengmin|Patten, Christopher|Sheng, Shuqun|Hong, Jungil|Bai, Naisheng|Winnik, Bozena|Ho, Chi-Tang|Yang, Chung S
PMID: 12642472
8.
Journal: Clin Cancer Res. 2004 Aug 1;10(15):5151-9.
Title: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
Author: Rouits, Elisabeth|Boisdron-Celle, Michele|Dumont, Agnes|Guerin, Olivier|Morel, Alain|Gamelin, Erick
PMID: 15297419
9.
Journal: Carcinogenesis. 2004 Dec;25(12):2407-15. Epub 2004 Aug 19.
Title: Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk.
Author: van der Logt, E M J|Bergevoet, S M|Roelofs, H M J|van Hooijdonk, Z|te Morsche, R H M|Wobbes, T|de Kok, J B|Nagengast, F M|Peters, W H M
PMID: 15319294
10.
Journal: Pharmacogenomics. 2004 Oct;5(7):835-43.
Title: Pharmacogenetics of irinotecan toxicity.
Author: Marsh, Sharon|McLeod, Howard L
PMID: 15469406
11.
Journal: J Natl Cancer Inst. 2004 Nov 3;96(21):1585-92.
Title: Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Author: Mathijssen, Ron H J|de Jong, Floris A|van Schaik, Ron H N|Lepper, Erin R|Friberg, Lena E|Rietveld, Trinet|de Bruijn, Peter|Graveland, Wilfried J|Figg, William D|Verweij, Jaap|Sparreboom, Alex
PMID: 15523087
12.
Journal: Oncol Rep. 2005 Feb;13(2):185-91.
Title: UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry.
Author: Giuliani, Laura|Ciotti, Marco|Stoppacciaro, Antonella|Pasquini, Anna|Silvestri, Ida|De Matteis, Anna|Frati, Luigi|Agliano, Anna-Maria
PMID: 15643497
13.
Journal: Br J Cancer. 2005 Jan 31;92(2):259-64.
Title: Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.
Author: Glasgow, S C|Yu, J|Carvalho, L P|Shannon, W D|Fleshman, J W|McLeod, H L
PMID: 15655543
14.
Journal: World J Gastroenterol. 2005 Feb 14;11(6):797-802.
Title: Polymorphisms of uridine-diphosphoglucuronosyltransferase 1A7 gene in Taiwan Chinese.
Author: Huang, May-Jen|Yang, Sien-Sing|Lin, Min-Shung|Huang, Ching-Shan
PMID: 15682470
15.
Journal: Biol Pharm Bull. 2005 Feb;28(2):271-4.
Title: The effects of coffee on conjugation reactions in human colon carcinoma cells.
Author: Okamura, Shigeaki|Suzuki, Keiko|Yanase, Masayo|Koizumi, Masumi|Tamura, Hiro-omi
PMID: 15684482
16.
Journal: Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
Title: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Author: Carlini, Leslie E|Meropol, Neal J|Bever, John|Andria, Michael L|Hill, Todd|Gold, Philip|Rogatko, Andre|Wang, Hao|Blanchard, Rebecca L
PMID: 15709193
17.
Journal: Am J Pharmacogenomics. 2005;5(1):21-33.
Title: Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Author: Lentz, Frederike|Tran, Agnes|Rey, Elisabeth|Pons, Gerard|Treluyer, Jean-Marc
PMID: 15727486
18.
Journal: World J Gastroenterol. 2005 Jun 7;11(21):3250-4.
Title: Link between colorectal cancer and polymorphisms in the uridine-diphosphoglucuronosyltransferase 1A7 and 1A1 genes.
Author: Tang, Kung-Sheng|Chiu, Hui-Fen|Chen, Hong-Hwa|Eng, Hock-Liew|Tsai, Chia-Jung|Teng, Hsiu-Chen|Huang, Ching-Shan
PMID: 15929176
19.
Journal: Clin Cancer Res. 2005 Jun 1;11(11):4144-50.
Title: A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Author: Wright, Maurice A|Morrison, Geraldine|Lin, Pengxin|Leonard, Gregory D|Nguyen, Dat|Guo, Xaiodu|Szabo, Eva|Hopkins, Jon L|Leguizamo, Jorge P|Harold, Nancy|Fioravanti, Suzanne|Schuler, Barbara|Monahan, Brian P|Saif, M Wasif|Quinn, Mary G|Pang, Janet|Grem, Je
PMID: 15930350
20.
Journal: Zhonghua Yi Xue Za Zhi. 2005 Mar 30;85(12):819-24.
Title: [Induction of uridine 5'-diphosphate-glucuronosyltransferase gene expression by sulforaphane and its mechanism: experimental study in human colon cancel cells].
Author: Wang, Min|Li, Yan-Qing|Zhong, Ning|Chen, Jian|Xu, Xiao-Qun|Yuan, Meng-Biao
PMID: 15949398
21.
Journal: J Biomed Sci. 2005;12(3):445-50.
Title: Molecular genetics of unconjugated hyperbilirubinemia in Taiwanese.
Author: Huang, Ching-Shan
PMID: 15965581
22.
Journal: Methods Enzymol. 2005;400:618-27.
Title: Cancer and molecular biomarkers of phase 2.
Author: Dalhoff, Kim|Buus Jensen, Kaspar|Enghusen Poulsen, Henrik
PMID: 16399374
23.
Journal: Cancer Chemother Pharmacol. 2006 Feb;57(3):309-16. Epub 2005 Jul 8.
Title: A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
Author: Tobin, Peter J|Beale, Philip|Noney, Leesa|Liddell, Sandy|Rivory, Laurent P|Clarke, Stephen
PMID: 16003560
24.
Journal: Cancer. 2006 Mar 1;106(5):1007-16.
Title: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Author: Massacesi, Cristian|Terrazzino, Salvatore|Marcucci, Fabiana|Rocchi, Marco B|Lippe, Paolo|Bisonni, Renato|Lombardo, Marco|Pilone, Alberta|Mattioli, Rodolfo|Leon, Alberta
PMID: 16456808
25.
Journal: Clin Cancer Res. 2006 Mar 15;12(6):1850-8.
Title: Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.
Author: Gagnon, Jean-Francois|Bernard, Olivier|Villeneuve, Lyne|Tetu, Bernard|Guillemette, Chantal
PMID: 16551870
26.
Journal: Zhonghua Yi Xue Za Zhi. 2006 Jan 10;86(2):82-7.
Title: [The role of NF-E2-related factor 2 in the induction of uridine 5'-diphosphate-glucuronosyltransferase 1A and its isoforms by epigallocatechin gallate in colon cancer cells].
Author: Yang, Xiao-yun|Zhao, Wei-ping|Li, Yan-qing|Sun, Zi-yuan|Zhang, Yan|Guo, Yu-ting|Yuan, Jun-hua|Zhu, Qiang|Wang, Min
PMID: 16620709
27.
Journal: Am J Health Syst Pharm. 2006 May 1;63(9 Suppl 2):S12-7.
Title: Individualizing chemotherapeutic treatment of colorectal cancer.
Author: Crews, Kristine R
PMID: 16641252
28.
Journal: Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R89-93.
Title: Pharmacogenomics: from bedside to clinical practice.
Author: Marsh, Sharon|McLeod, Howard L
PMID: 16651374
29.
Journal: Biol Pharm Bull. 2006 Jul;29(7):1476-9.
Title: Turmeric and curcumin modulate the conjugation of 1-naphthol in Caco-2 cells.
Author: Naganuma, Megumi|Saruwatari, Ayako|Okamura, Shigeaki|Tamura, Hiroomi
PMID: 16819192
30.
Journal: Anticancer Res. 2006 May-Jun;26(3B):2189-96.
Title: Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.
Author: Cummings, Jeffrey|Ethell, Brian T|Jardine, Lesley|Burchell, Brian
PMID: 16821585
31.
Journal: Oncol Rep. 2006 Sep;16(3):497-503.
Title: Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.
Author: Romero, R Zarate|Morales, R|Garcia, F|Huarriz, M|Bandres, E|De la Haba, J|Gomez, A|Aranda, E|Garcia-Foncillas, J
PMID: 16865249
32.
Journal: Drug Metab Rev. 2006;38(3):393-409.
Title: Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Author: Nagar, Swati|Blanchard, Rebecca L
PMID: 16877259
33.
Journal: Cancer Invest. 2006 Oct;24(6):630-9.
Title: Pharmacogenomics of colorectal cancer prevention and treatment.
Author: Nguyen, Hoa|Tran, Ashley|Lipkin, Steven|Fruehauf, John P
PMID: 16982469
34.
Journal: Oncol Rep. 2006 Nov;16(5):971-4.
Title: Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.
Author: Inoue, Yasuhiro|Miki, Chikao|Watanabe, Hideki|Hiro, Junichiro|Toiyama, Yuji|Ojima, Eiki|Nakatani, Kaname|Nobori, Tsutomu|Kusunoki, Masato
PMID: 17016579
35.
Journal: Neoplasma. 2006;53(6):463-70.
Title: Isothiocyanate iberin modulates phase II enzymes, posttranslational modification of histones and inhibits growth of Caco-2 cells by inducing apoptosis.
Author: Jakubikova, J|Bao, Y|Bodo, J|Sedlak, J
PMID: 17167713
36.
Journal: Oncol Rep. 2007 Mar;17(3):637-45.
Title: Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa
Author: Martinez-Balibrea, Eva|Manzano, Jose Luis|Martinez-Cardus, Anna|Moran, Teresa|Cirauqui, Beatriz|Catot, Silvia|Taron, Miguel|Abad, Albert
PMID: 17273745
37.
Journal: Carcinogenesis. 2007 Nov;28(11):2412-8. Epub 2007 Jul 17.
Title: Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10.
Author: Dellinger, Ryan W|Chen, Gang|Blevins-Primeau, Andrea S|Krzeminski, Jacek|Amin, Shantu|Lazarus, Philip
PMID: 17638922
38.
Journal: Pharmacology. 2007;80(4):269-78. Epub 2007 Jul 26.
Title: Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice.
Author: Yuan, Jun-Hua|Li, Yan-Qing|Yang, Xiao-Yun
PMID: 17657175
39.
Journal: Zhonghua Zhong Liu Za Zhi. 2007 Dec;29(12):913-6.
Title: [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Author: Wang, Yan|Xu, Jian-Ming|Shen, Lin|Xu, Nong|Wang, Jin-Wan|Jiao, Shun-Chang|Zhang, Jing-Sheng|Song, San-Tai|Li, Jian|Bao, Han-Ying|Yang, Lin|Li, Fang
PMID: 18478930
40.
Journal: Pharmacogenomics J. 2008 Aug;8(4):278-88.
Title: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
Author: Ruzzo, A|Graziano, F|Loupakis, F|Santini, D|Catalano, V|Bisonni, R|Ficarelli, R|Fontana, A|Andreoni, F|Falcone, A|Canestrari, E|Tonini, G|Mari, D|Lippe, P|Pizzagalli, F|Schiavon, G|Alessandroni, P|Giustini, L|Maltese, P|Testa, E|Menichetti, E T|Magnani, M
PMID: 17549067
41.
Journal: Cancer. 2008 May 1;112(9):1932-40.
Title: UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Author: Liu, Chun-Yu|Chen, Po-Min|Chiou, Tzeon-Jye|Liu, Jin-Hwang|Lin, Jen-Kou|Lin, Tzu-Chen|Chen, Wei-Shone|Jiang, Jeng-Kae|Wang, Huann-Sheng|Wang, Wei-Shu
PMID: 18300238
42.
Journal: Mod Pathol. 2008 May;21 Suppl 2:S23-30.
Title: Targeted therapy of cancer: new roles for pathologists in colorectal cancer.
Author: Hamilton, Stanley R
PMID: 18437170
43.
Journal: Pharmacogenomics. 2008 May;9(5):539-49.
Title: Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.
Author: Obradovic, Marko|Mrhar, Ales|Kos, Mitja
PMID: 18466101
44.
Journal: Arch Toxicol. 2008 Jul;82(7):415-33.
Title: Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Author: Strassburg, Christian P|Lankisch, Tim O|Manns, Michael P|Ehmer, Ursula
PMID: 18491077
45.
Journal: J Clin Oncol. 2008 Jun 1;26(16):2690-8.
Title: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Author: Braun, Michael S|Richman, Susan D|Quirke, Philip|Daly, Catherine|Adlard, Julian W|Elliott, Faye|Barrett, Jennifer H|Selby, Peter|Meade, Angela M|Stephens, Richard J|Parmar, Mahesh K B|Seymour, Matthew T
PMID: 18509181
46.
Journal: BMC Med Genomics. 2008 Jun 11;1:24.
Title: Genotyping panel for assessing response to cancer chemotherapy.
Author: Dai, Zunyan|Papp, Audrey C|Wang, Danxin|Hampel, Heather|Sadee, Wolfgang
PMID: 18547414
47.
Journal: Br J Cancer. 2008 Jul 22;99(2):275-82.
Title: UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Author: Kweekel, D M|Gelderblom, H|Van der Straaten, T|Antonini, N F|Punt, C J A|Guchelaar, H-J
PMID: 18594531
48.
Journal: Mutat Res. 2008 Sep 26;644(1-2):56-63.
Title: UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans.
Author: Girard, Hugo|Butler, Lesley M|Villeneuve, Lyne|Millikan, Robert C|Sinha, Rashmi|Sandler, Robert S|Guillemette, Chantal
PMID: 18675828
49.
Journal: Pharmacogenomics. 2008 Aug;9(8):1079-99.
Title: Pharmacogenetics in colorectal cancer: a systematic review.
Author: Funke, Silvia|Brenner, Hermann|Chang-Claude, Jenny
PMID: 18681783
50.
Journal: Br J Cancer. 2008 Oct 21;99(8):1239-45.
Title: Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Author: Rouits, E|Charasson, V|Petain, A|Boisdron-Celle, M|Delord, J-P|Fonck, M|Laurand, A|Poirier, A-L|Morel, A|Chatelut, E|Robert, J|Gamelin, E
PMID: 18797458
51.
Journal: Bull Cancer. 2008 Oct;95(10):931-4.
Title: [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].
Author: Ducreux, Michel|Boige, Valerie|Malka, David|Laurent-Puig, Pierre
PMID: 19004722
52.
Journal: Bull Cancer. 2008 Oct;95(10):935-42.
Title: [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Author: Laurent-Puig, Pierre|Lievre, Astrid|Ducreux, Michel|Loriot, Marie-Anne
PMID: 19004723
53.
Journal: Clin Lab Med. 2008 Dec;28(4):553-67.
Title: Pharmacogenomics of tamoxifen and irinotecan therapies.
Author: Algeciras-Schimnich, Alicia|O'Kane, Dennis J|Snozek, Christine L H
PMID: 19059062
54.
Journal: Arch Drug Inf. 2008 Dec;1(3):97-106.
Title: Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer.
Author: Parodi, Luis|Pickering, Eve|Cisar, Laura A|Lee, Doug|Soufi-Mahjoubi, Raoudha
PMID: 19639031
55.
Journal: Pharmacogenet Genomics. 2009 Feb;19(2):113-20.
Title: C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps.
Author: Poole, Elizabeth M|Bigler, Jeannette|Whitton, John|Sibert, Justin G|Potter, John D|Ulrich, Cornelia M
PMID: 19077918
56.
Journal: Genet Med. 2009 Jan;11(1):21-34.
Title: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
Author: Palomaki, Glenn E|Bradley, Linda A|Douglas, Michael P|Kolor, Katherine|Dotson, W David
PMID: 19125129
57.
Journal: J Clin Oncol. 2009 May 20;27(15):2457-65.
Title: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Author: Cecchin, Erika|Innocenti, Federico|D'Andrea, Mario|Corona, Giuseppe|De Mattia, Elena|Biason, Paola|Buonadonna, Angela|Toffoli, Giuseppe
PMID: 19364970
58.
Journal: Best Pract Res Clin Gastroenterol. 2009;23(2):257-73.
Title: Pharmacogenetics in chemotherapy of colorectal cancer.
Author: Henriette Tanja, Lieke|Guchelaar, Henk-Jan|Gelderblom, Hans
PMID: 19414151
59.
Journal: Pharmacogenomics. 2009 May;10(5):733-9.
Title: UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
Author: Ferraldeschi, Roberta|Minchell, Laura J|Roberts, Stephen A|Tobi, Simon|Hadfield, Kristen D|Blackhall, Fiona H|Mullamitha, Saifee|Wilson, Gregory|Valle, Juan|Saunders, Mark|Newman, William G
PMID: 19450125
60.
Journal: JOP. 2009 Jul 6;10(4):357-60.
Title: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Author: Strimpakos, Alexios S|Syrigos, Kostas N|Saif, Muhammad Wasif
PMID: 19581734
61.
Journal: Gan To Kagaku Ryoho. 2009 Jul;36(7):1159-61.
Title: [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
Author: Yokoyama, Satoshi|Imamura, Yuuji|Hatano, Naoto|Fukuoka, Tatsuhito|Usui, Hirofumi|Morita, Yasushi
PMID: 19620808
62.
Journal: J Mol Diagn. 2009 Sep;11(5):381-9.
Title: Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
Author: Snozek, Christine L H|O'Kane, Dennis J|Algeciras-Schimnich, Alicia
PMID: 19644023
63.
Journal: Clin Cancer Res. 2009 Sep 1;15(17):5528-33.
Title: Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Author: Bosman, Fred T|Yan, Pu|Tejpar, Sabine|Fiocca, Roberto|Van Cutsem, Eric|Kennedy, Richard D|Dietrich, Daniel|Roth, Arnaud
PMID: 19690194
64.
Journal: Chin Med J (Engl). 2009 Jul 20;122(14):1660-5.
Title: Modulation of NRF2 and UGT1A expression by epigallocatechin-3-gallate in colon cancer cells and BALB/c mice.
Author: Zhang, Zhi-mian|Yang, Xiao-yun|Yuan, Jun-hua|Sun, Zi-yuan|Li, Yan-qing
PMID: 19719968
65.
Journal: Genome Med. 2009 Sep 4;1(9):83.
Title: Networking of differentially expressed genes in human cancer cells resistant to methotrexate.
Author: Selga, Elisabet|Oleaga, Carlota|Ramirez, Sara|de Almagro, M Cristina|Noe, Veronique|Ciudad, Carlos J
PMID: 19732436
66.
Journal: J Clin Oncol. 2009 Nov 20;27(33):5519-28.
Title: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Author: Braun, Michael S|Richman, Susan D|Thompson, Lindsay|Daly, Catherine L|Meade, Angela M|Adlard, Julian W|Allan, James M|Parmar, Mahesh K B|Quirke, Philip|Seymour, Matthew T
PMID: 19858398
67.
Journal: Oncol Rep. 2010 Jan;23(1):191-7.
Title: CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.
Author: Hiraki, Masatsugu|Kitajima, Yoshihiko|Nakafusa, Yuji|Nakamura, Jun|Hashiguchi, Kazuyoshi|Sumi, Kenji|Noshiro, Hirokazu|Miyazaki, Kohji
PMID: 19956881
68.
Journal: Pharmacogenomics J. 2010 Oct;10(5):431-41.
Title: Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines.
Author: Bellemare, J|Rouleau, M|Harvey, M|Tetu, B|Guillemette, C
PMID: 19997083
69.
Journal: Cancer Sci. 2010 Mar;101(3):722-7.
Title: Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
Author: Hazama, Shoichi|Nagashima, Atsushi|Kondo, Hiroshi|Yoshida, Shin|Shimizu, Ryoichi|Araki, Atsuhiro|Yoshino, Shigefumi|Okayama, Naoko|Hinoda, Yuji|Oka, Masaaki
PMID: 20028383
70.
Journal: Bull Cancer. 2010 Feb;97(2):265-80.
Title: [Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer].
Author: Bouche, O|Scaglia, E|Lagarde, S
PMID: 20080456
71.
Journal: BMC Mol Biol. 2010 Jan 22;11:9.
Title: Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells.
Author: Belanger, Anne-Sophie|Tojcic, Jelena|Harvey, Mario|Guillemette, Chantal
PMID: 20096102
72.
Journal: Mol Cancer. 2010 Mar 2;9:46.
Title: Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Author: Raynal, Caroline|Pascussi, Jean-Marc|Leguelinel, Geraldine|Breuker, Cyril|Kantar, Jovana|Lallemant, Benjamin|Poujol, Sylvain|Bonnans, Caroline|Joubert, Dominique|Hollande, Frederic|Lumbroso, Serge|Brouillet, Jean-Paul|Evrard, Alexandre
PMID: 20196838
73.
Journal: Br J Cancer. 2010 Aug 10;103(4):581-9.
Title: UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Author: Martinez-Balibrea, E|Abad, A|Martinez-Cardus, A|Gines, A|Valladares, M|Navarro, M|Aranda, E|Marcuello, E|Benavides, M|Massuti, B|Carrato, A|Layos, L|Manzano, J L|Moreno, V
PMID: 20628391
74.
Journal: Ann Pharm Fr. 2010 Jul;68(4):233-53.
Title: [Recent developments of pharmacogenomics in the treatment of colorectal cancers].
Author: Astier, A
PMID: 20637356
75.
Journal: Br J Cancer. 2010 Jul 27;103(3):315-23.
Title: Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Author: Shabaruddin, F H|Elliott, R A|Valle, J W|Newman, W G|Payne, K
PMID: 20661248
76.
Journal: J Pharm Pharm Sci. 2010;13(4):615-25.
Title: Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
Author: Pichereau, Solen|Le Louarn, Anne|Lecomte, Thierry|Blasco, Helene|Le Guellec, Chantal|Bourgoin, Helene
PMID: 21486535
77.
Journal: Pharmacogenomics J. 2011 Feb;11(1):61-71.
Title: Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Author: Glimelius, B|Garmo, H|Berglund, A|Fredriksson, L A|Berglund, M|Kohnke, H|Bystrom, P|Sorbye, H|Wadelius, M
PMID: 20177420
78.
Journal: Ann Oncol. 2011 Feb;22(2):355-61.
Title: Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.
Author: Tsunoda, A|Nakao, K|Watanabe, M|Matsui, N|Ooyama, A|Kusano, M
PMID: 20647221
79.
Journal: Cancer Chemother Pharmacol. 2011 Jan;67(1):231-6.
Title: Effects of methimazole on the elimination of irinotecan.
Author: van der Bol, Jessica M|Visser, Theo J|Loos, Walter J|de Jong, Floris A|Wiemer, Erik A C|van Aken, Maarten O|Planting, Andre S|Schellens, Jan H|Verweij, Jaap|Mathijssen, Ron H J
PMID: 20680278
80.
Journal: Cancer Chemother Pharmacol. 2011 Aug;68(2):279-84.
Title: UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Author: Sunakawa, Yu|Ichikawa, Wataru|Fujita, Ken-Ichi|Nagashima, Fumio|Ishida, Hiroo|Yamashita, Keishi|Mizuno, Keiko|Miwa, Keisuke|Kawara, Kaori|Akiyama, Yuko|Araki, Kazuhiro|Yamamoto, Wataru|Miya, Toshimichi|Narabayashi, Masaru|Ando, Yuichi|Hirose, Takashi|Saji
PMID: 20957480
81.
Journal: Jpn J Clin Oncol. 2011 Feb;41(2):204-9.
Title: Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Author: Yamashita, Keishi|Nagashima, Fumio|Fujita, Ken-ichi|Yamamoto, Wataru|Endo, Hisashi|Miya, Toshimichi|Narabayashi, Masaru|Kawara, Kaori|Akiyama, Yuko|Ando, Yuichi|Ando, Masahiko|Sasaki, Yasutsuna
PMID: 20965940
82.
Journal: J Pathol. 2011 Feb;223(3):425-35.
Title: Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans.
Author: Bellemare, Judith|Rouleau, Melanie|Harvey, Mario|Popa, Ion|Pelletier, Georges|Tetu, Bernard|Guillemette, Chantal
PMID: 21171088
83.
Journal: Cancer. 2011 Jul 15;117(14):3156-62.
Title: Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
Author: Shulman, Katerina|Cohen, Ilana|Barnett-Griness, Ofra|Kuten, Abraham|Gruber, Stephen B|Lejbkowicz, Flavio|Rennert, Gad
PMID: 21287524
84.
Journal: Jpn J Clin Oncol. 2011 May;41(5):617-23.
Title: Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Author: Ishida, Hiroo|Fujita, Ken-Ichi|Akiyama, Yuko|Sunakawa, Yu|Yamashita, Keishi|Mizuno, Keiko|Miwa, Keisuke|Kawara, Kaori|Ichikawa, Wataru|Ando, Yuichi|Saji, Shigehira|Sasaki, Yasutsuna
PMID: 21310730
85.
Journal: Mol Med Rep. 2011 Mar-Apr;4(2):203-8.
Title: Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).
Author: Aiello, Marco|Vella, Nadia|Cannavo, Calogero|Scalisi, Aurora|Spandidos, Demetrios A|Toffoli, Giuseppe|Buonadonna, Angela|Libra, Massimo|Stivala, Franca
PMID: 21468552
86.
Journal: Tumori. 2011 Mar-Apr;97(2):243-7.
Title: Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer.
Author: Huang, Sung-Hao|Chao, Yee|Wu, Ying-Ying|Luo, Jiing-Chyuan|Kao, Chien-Hui|Yen, Sang-Hue|Li, Chung-Pin
PMID: 21617725
87.
Journal: Br J Cancer. 2011 Jun 28;105(1):53-7.
Title: A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Author: Marcuello, E|Paez, D|Pare, L|Salazar, J|Sebio, A|del Rio, E|Baiget, M
PMID: 21654688
88.
Journal: PLoS Comput Biol. 2011 Sep;7(9):e1002143.
Title: A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.
Author: Ballesta, Annabelle|Dulong, Sandrine|Abbara, Chadi|Cohen, Boris|Okyar, Alper|Clairambault, Jean|Levi, Francis
PMID: 21931543
89.
Journal: Br J Cancer. 2011 Nov 22;105(11):1654-62.
Title: Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.
Author: Thomas, F|Motsinger-Reif, A A|Hoskins, J M|Dvorak, A|Roy, S|Alyasiri, A|Myerson, R J|Fleshman, J W|Tan, B R|McLeod, H L
PMID: 22045187
90.
Journal: Colorectal Dis. 2012 Jan;14(1):3-17.
Title: Review of biomarkers in colorectal cancer.
Author: Newton, K F|Newman, W|Hill, J
PMID: 21040359
91.
Journal: Dig Liver Dis. 2012 Jan;44(1):74-9.
Title: Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients.
Author: Scartozzi, Mario|Loretelli, Cristian|Berardi, Rossana|Pierantoni, Chiara|Silva, Rosa Rita|Mari, Davide|Giampieri, Riccardo|Faloppi, Luca|Pistelli, Mirco|Maccaroni, Elena|Bittoni, Alessandro|Del Prete, Michela|Galizia, Eva|Cascinu, Stefano
PMID: 21893437
92.
Journal: Int J Cancer. 2012 Oct 1;131(7):1549-55.
Title: Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer.
Author: Jiraskova, Alena|Novotny, Jan|Novotny, Ladislav|Vodicka, Pavel|Pardini, Barbara|Naccarati, Alessio|Schwertner, Harvey A|Hubacek, Jaroslav A|Puncocharova, Lucie|Smerhovsky, Zdenek|Vitek, Libor
PMID: 22212955
93.
Journal: Cancer Chemother Pharmacol. 2012 Apr;69(4):1107-11.
Title: Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.
Author: Cao, Shousong|Durrani, Farukh A|Rustum, Youcef M|Yu, Y Eugene
PMID: 22237959
94.
Journal: Oncology. 2012;82(4):242-8.
Title: A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Author: Sunakawa, Yu|Fujita, Ken-ichi|Ichikawa, Wataru|Ishida, Hiroo|Yamashita, Keishi|Araki, Kazuhiro|Miwa, Keisuke|Kawara, Kaori|Akiyama, Yuko|Yamamoto, Wataru|Nagashima, Fumio|Saji, Shigehira|Sasaki, Yasutsuna
PMID: 22508373
95.
Journal: Carcinogenesis. 2012 Jul;33(7):1332-9.
Title: Meat-related mutagen exposure, xenobiotic metabolizing gene polymorphisms and the risk of advanced colorectal adenoma and cancer.
Author: Gilsing, Anne M J|Berndt, Sonja I|Ruder, Elizabeth H|Graubard, Barry I|Ferrucci, Leah M|Burdett, Laura|Weissfeld, Joel L|Cross, Amanda J|Sinha, Rashmi
PMID: 22552404
96.
Journal: Chin J Physiol. 2012 Apr 30;55(2):134-44.
Title: Effects of phytochemicals sulforaphane on uridine diphosphate-glucuronosyltransferase expression as well as cell-cycle arrest and apoptosis in human colon cancer Caco-2 cells.
Author: Wang, Min|Chen, Shuo|Wang, Shuai|Sun, Defeng|Chen, Jian|Li, Yanqing|Han, Wei|Yang, Xiaoyun|Gao, Hai-Qing
PMID: 22559738
97.
Journal: Cancer Genet. 2012 Apr;205(4):163-7.
Title: Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer.
Author: Bajro, Marija Hiljadnikova|Josifovski, Toni|Panovski, Milco|Jankulovski, Nikola|Nestorovska, Aleksandra Kapedanovska|Matevska, Nadica|Petrusevska, Natalija|Dimovski, Aleksandar J
PMID: 22559977
98.
Journal: Int J Clin Exp Med. 2012;5(2):186-94. Epub 2012 Apr 6.
Title: ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese.
Author: Chai, Haina|Pan, Jie|Zhang, Xuelin|Zhang, Xiaoyan|Shen, Xiaoying|Li, Hang|Zhang, Kehao|Yang, Changqing|Sheng, Haihui|Gao, Hengjun
PMID: 22567180
99.
Journal: Cancer Chemother Pharmacol. 2012 Jul;70(1):25-32.
Title: Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Author: Chiorean, E Gabriela|Sanghani, Sonal|Schiel, Marissa A|Yu, Menggang|Burns, Matthew|Tong, Yan|Hinkle, David T|Coleman, Nicki|Robb, Bruce|LeBlanc, Julia|Clark, Romnee|Bufill, Jose|Curie, Colleen|Loehrer, Patrick J|Cardenes, Higinia
PMID: 22610353
100.
Journal: Cancer. 2012 Dec 15;118(24):6144-51.
Title: Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
Author: Kurzrock, Razelle|Goel, Sanjay|Wheler, Jennifer|Hong, David|Fu, Siqing|Rezai, Keyvan|Morgan-Linnell, Sonia K|Urien, Saik|Mani, Sridhar|Chaudhary, Imran|Ghalib, Mohammed H|Buchbinder, Aby|Lokiec, Francois|Mulcahy, Mary
PMID: 22674635
101.
Journal: Oncol Lett. 2012 Mar;3(3):694-698.
Title: Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.
Author: Hirose, Koichi|Kozu, Chihiro|Yamashita, Koshiro|Maruo, Eiji|Kitamura, Mizuho|Hasegawa, Junichi|Omoda, Kei|Murakami, Teruo|Maeda, Yorinobu
PMID: 22740978
102.
Journal: Pharmacogenomics. 2012 Jul;13(10):1173-91.
Title: Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
Author: Cortejoso, Lucia|Lopez-Fernandez, Luis A
PMID: 22909207
103.
Journal: Zhonghua Nei Ke Za Zhi. 2012 Jul;51(7):531-5.
Title: [The UGT1A, Nrf2 and Keap1 protein expression and significance in colon tumor].
Author: Wang, Min|Qi, Ying-ying|Chen, Shuo|Liu, Liang|Chen, Jian|Li, Yan-qing
PMID: 22943825
104.
Journal: Carcinogenesis. 2012 Dec;33(12):2311-9.
Title: Splice isoforms as therapeutic targets for colorectal cancer.
Author: Miura, Koh|Fujibuchi, Wataru|Unno, Michiaki
PMID: 23118106
105.
Journal: J Cancer Epidemiol. 2012;2012:294730.
Title: Patterns of cancer genetic testing: a randomized survey of Oregon clinicians.
Author: Cox, Summer L|Zlot, Amy I|Silvey, Kerry|Elliott, Debi|Horn, Tara|Johnson, Amber|Leman, Richard F
PMID: 23150730
106.
Journal: World J Gastroenterol. 2012 Dec 7;18(45):6635-44.
Title: UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Author: Wang, Yan|Shen, Lin|Xu, Nong|Wang, Jin-Wan|Jiao, Shun-Chang|Liu, Ze-Yuan|Xu, Jian-Ming
PMID: 23236239
107.
Journal: Rinsho Byori. 2012 Oct;60(10):976-81.
Title: [Genetic and epigenetic changes in colorectal cancer and genetic testing for personalized medicine].
Author: Suehiro, Yutaka|Hinoda, Yuji
PMID: 23323463
108.
Journal: Acta Medica (Hradec Kralove). 2012;55(4):153-9.
Title: Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.
Author: Paulik, Adam|Grim, Jiri|Filip, Stanislav
PMID: 23631285
109.
Journal: Tohoku J Exp Med. 2013;229(2):107-14.
Title: Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Author: Inoue, Kazuyuki|Sonobe, Momoyo|Kawamura, Yukinori|Etoh, Takashi|Takagi, Masakazu|Matsumura, Takashi|Kikuyama, Masataka|Kimura, Midori|Minami, Sato|Utsuki, Hiroaki|Yamazaki, Tomoaki|Suzuki, Takayo|Tsuji, Daiki|Hayashi, Hideki|Itoh, Kunihiko
PMID: 23303296
110.
Journal: J Pharmacol Exp Ther. 2013 Apr;345(1):95-101.
Title: Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Author: Levesque, Eric|Belanger, Anne-Sophie|Harvey, Mario|Couture, Felix|Jonker, Derek|Innocenti, Federico|Cecchin, Erica|Toffoli, Giuseppe|Guillemette, Chantal
PMID: 23386248
111.
Journal: PLoS One. 2013;8(2):e57045.
Title: Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancer.
Author: Wang, Min|Sun, De-Feng|Wang, Shuai|Qing, Ying|Chen, Shuo|Wu, Dong|Lin, Ying-Min|Luo, Ji-Zhuang|Li, Yan-Qing
PMID: 23468910
112.
Journal: PLoS One. 2013;8(3):e58489.
Title: Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.
Author: Liu, Xiang|Cheng, Dangxiao|Kuang, Qin|Liu, Geoffrey|Xu, Wei
PMID: 23516488
113.
Journal: Cancer Chemother Pharmacol. 2013 Jun;71(6):1463-72.
Title: Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
Author: Cortejoso, Lucia|Garcia, Maria I|Garcia-Alfonso, Pilar|Gonzalez-Haba, Eva|Escolar, Fernando|Sanjurjo, Maria|Lopez-Fernandez, Luis A
PMID: 23543295
114.
Journal: Curr Drug Targets. 2013 Jun;14(7):777-97.
Title: Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Author: Swami, Umang|Goel, Sanjay|Mani, Sridhar
PMID: 23597015
115.
Journal: Zhonghua Yi Xue Za Zhi. 2013 Feb 26;93(8):614-8.
Title: [Effects of autophagy modulator on autophagy and uridine 5'-diphospho-glucuronosyltransferase 1A1 induced by sulforaphane].
Author: Wang, Min|Chen, Shuo|Qing, Ying|Wu, Dong|Lin, Ying-min|Chen, Jian|Li, Yan-qing
PMID: 23663345
116.
Journal: Med Oncol. 2013;30(3):604.
Title: UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Author: Gao, Jing|Zhou, Jun|Li, Yanyan|Lu, Ming|Jia, Ru|Shen, Lin
PMID: 23686699
117.
Journal: J Cancer Res Clin Oncol. 2013 Sep;139(9):1579-89.
Title: Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Author: Cai, Xun|Cao, Weiguo|Ding, Honghua|Liu, Tianshu|Zhou, Xinli|Wang, Mei|Zhong, Ming|Zhao, Ziyi|Xu, Qing|Wang, Liwei
PMID: 23892411
118.
Journal: Neoplasma. 2013 Sep 20.
Title: The role of tumor markers and biomarkers in colorectal cancer.
Author: Lech, G|Slotwinski, R|Krasnodebski, I W
PMID: 24050544
119.
Journal: PLoS One. 2013 Nov 14;8(11):e79172.
Title: UDP-glucuronosyltransferase 1A compromises intracellular accumulation and anti-cancer effect of tanshinone IIA in human colon cancer cells.
Author: Liu, Miao|Wang, Qiong|Liu, Fang|Cheng, Xuefang|Wu, Xiaolan|Wang, Hong|Wu, Mengqiu|Ma, Ying|Wang, Guangji|Hao, Haiping
PMID: 24244442
120.
Journal: J Oncol Pharm Pract. 2014 Feb;20(1):11-28.
Title: Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.
Author: Chung, Clement|Christianson, Matthew
PMID: 23493335
121.
Journal: Pharmacogenomics J. 2014 Apr;14(2):120-9.
Title: Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
Author: Liu, X|Cheng, D|Kuang, Q|Liu, G|Xu, W
PMID: 23529007
122.
Journal: Int J Clin Oncol. 2014 Apr;19(2):397-402.
Title: Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
Author: Hirose, Kouichi|Yamashita, Koushiro|Takada, Hirofumi|Kaneda, Noriko|Fukami, Kohei|Maruo, Eiji|Kitamura, Mizuho|Hasegawa, Junichi|Maeda, Yorinobu
PMID: 23605141
123.
Journal: Neoplasma. 2014;61(1):1-8.
Title: The role of tumor markers and biomarkers in colorectal cancer.
Author: Lech, G|Slotwinski, R|Krasnodebski, I W
PMID: 24195503
124.
Journal: Neoplasma. 2014;61(1):99-109.
Title: Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation.
Author: Xie, F W|Peng, Y|Chen, Xiong|Chen, Xi|Li, J|Wang, W|Yu, Z|Ouyang, X
PMID: 24195516
125.
Journal: J Surg Oncol. 2014 Mar;109(3):250-4.
Title: Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
Author: Kim, Do Yoon|Paek, Tae Yoon|Oh, Seung Yeop|Kim, Young Bae|Lee, Je Hee|Lee, Mi Young|Choi, Zi Sun|Suh, Kwang Wook
PMID: 24318863
126.
Journal: J Clin Pharmacol. 2014 May;54(5):495-502.
Title: Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Author: Suenaga, Mitsukuni|Fuse, Nozomu|Yamaguchi, Tatsuro|Yamanaka, Yasuhiro|Motomura, Shigeki|Matsumoto, Hiroshi|Hamamoto, Yasuo|Mizunuma, Nobuyuki|Doi, Toshihiko|Hatake, Kiyohiko|Iwasaki, Junko|Ohtsu, Atsushi
PMID: 24382596
127.
Journal: Anticancer Res. 2014 Jan;34(1):195-201.
Title: Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Author: Hirata, Keiji|Nagata, Naoki|Kato, Takeshi|Okuyama, Yusuke|Andoh, Hideaki|Takahashi, Kenichi|Oba, Koji|Sakamoto, Junichi|Hazama, Shoichi|Mishima, Hideyuki
PMID: 24403462
128.
Journal: Biomed Pharmacother. 2014 Feb;68(1):31-7.
Title: Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells.
Author: Xie, Fang-Wei|Peng, Yong-Hai|Chen, Xi|Chen, Xiong|Li, Jie|Yu, Zong-Yang|Wang, Wen-Wu|Ouyang, Xue-Nong
PMID: 24439671
129.
Journal: Exp Mol Pathol. 2014 Feb;96(1):15-26.
Title: Modulatory effect of troxerutin on biotransforming enzymes and preneoplasic lesions induced by 1,2-dimethylhydrazine in rat colon carcinogenesis.
Author: Vinothkumar, Rajamanickam|Vinoth Kumar, Rajenderan|Sudha, Mani|Viswanathan, Periyaswamy|Balasubramanian, Thangavel|Nalini, Namasivayam
PMID: 24512697
130.
Journal: Food Funct. 2014 Jun;5(6):1073-81.
Title: Glucosinolates from pak choi and broccoli induce enzymes and inhibit inflammation and colon cancer differently.
Author: Lippmann, Doris|Lehmann, Carsten|Florian, Simone|Barknowitz, Gitte|Haack, Michael|Mewis, Inga|Wiesner, Melanie|Schreiner, Monika|Glatt, Hansruedi|Brigelius-Flohe, Regina|Kipp, Anna P
PMID: 24714741
131.
Journal: BMC Res Notes. 2014 Apr 23;7:260.
Title: FOLFIRI(R) and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.
Author: Becouarn, Yves|Cany, Laurent|Pulido, Marina|Beyssac, Richard|Texereau, Patrick|Le Morvan, Valerie|Bechade, Dominique|Brunet, Rene|Aitouferoukh, Sofiane|Lalet, Caroline|Mathoulin-Pelissier, Simone|Fonck, Marianne|Robert, Jacques
PMID: 24758527
132.
Journal: Genes Chromosomes Cancer. 2014 Jun;53(6):454-66.
Title: The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene-environment interactions.
Author: Angstadt, Andrea Y|Hartman, Terryl J|Lesko, Samuel M|Muscat, Joshua E|Zhu, Junjia|Gallagher, Carla J|Lazarus, Philip
PMID: 24822274
133.
Journal: Bull Cancer. 2014 Jun;101(6):533-53.
Title: [Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Author: Boyer, Jean-Christophe|Etienne-Grimaldi, Marie-Christine|Thomas, Fabienne|Quaranta, Sylvie|Picard, Nicolas|Loriot, Marie-Anne|Poncet, Delphine|Gagnieu, Marie-Claude|Ged, Cecile|Broly, Franck|Le Morvan, Valerie|Bouquie, Regis|Gaub, Marie-Pierre|Philibert,
PMID: 24977443
134.
Journal: Pharmacogenomics. 2014 Jun;15(9):1171-4.
Title: UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Author: Liu, Xiang|Xu, Wei
PMID: 25141892
135.
Journal: Ann Pharmacother. 2014 Dec;48(12):1646-50.
Title: The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
Author: Cruz, Joseph E|Saksena, Rujuta|Jabbour, Salma K|Nosher, John L|Hermes-DeSantis, Evelyn|Moss, Rebecca A
PMID: 25202035
136.
Journal: Cell Death Dis. 2014 Sep 11;5:e1411.
Title: UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
Author: Landmann, H|Proia, D A|He, S|Ogawa, L S|Kramer, F|Beissbarth, T|Grade, M|Gaedcke, J|Ghadimi, M|Moll, U|Dobbelstein, M
PMID: 25210794
137.
Journal: Biomed Pharmacother. 2014 Sep;68(7):825-31.
Title: Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11.
Author: Xie, Fang-Wei|Peng, Yong-Hai|Wang, Wen-Wu|Chen, Xi|Chen, Xiong|Li, Jie|Yu, Zong-Yang|Ouyang, Xue-Nong
PMID: 25260839
138.
Journal: Oncol Lett. 2014 Dec;8(6):2407-2416.
Title: Effects of co-treatment with sulforaphane and autophagy modulators on uridine 5'-diphospho-glucuronosyltransferase 1A isoforms and cytochrome P450 3A4 expression in Caco-2 human colon cancer cells.
Author: Wang, Min|Zhu, Jing-Yu|Chen, Shuo|Qing, Ying|Wu, Dong|Lin, Ying-Min|Luo, Ji-Zhuang|Han, Wei|Li, Yan-Qing
PMID: 25364403
139.
Journal: Onco Targets Ther. 2014 Nov 21;7:2143-6.
Title: FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping.
Author: Lu, Chien-Yu|Yeh, Yung-Sung|Huang, Ching-Wen|Ma, Cheng-Jen|Yu, Fang-Jung|Wang, Jaw-Yuan
PMID: 25473295
140.
Journal: Value Health. 2014 Nov;17(7):A643.
Title: Cost-Effectiveness Analysis of Ugt1a1 Genotyping Before Colorectal Cancer Treatment with Irinotecan.
Author: Butzke, B|Oduncu, F|Heinemann, V|Pfeufer, A|Giessen, C|Stollenwerk, B|Rogowski, W
PMID: 27202308
141.
Journal: PLoS One. 2015 Feb 17;10(2):e0118194.
Title: Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study.
Author: Marangon, Elena|Posocco, Bianca|Mazzega, Elisa|Toffoli, Giuseppe
PMID: 25689738
142.
Journal: PLoS One. 2015 Feb 18;10(2):e0117051.
Title: UDP-glucuronosyltransferase 1A determinates intracellular accumulation and anti-cancer effect of beta-lapachone in human colon cancer cells.
Author: Liu, Huiying|Li, Qingran|Cheng, Xuefang|Wang, Hong|Wang, Guangji|Hao, Haiping
PMID: 25692465
143.
Journal: Br J Clin Pharmacol. 2015 Sep;80(3):581-8.
Title: DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Author: Falvella, Felicia Stefania|Cheli, Stefania|Martinetti, Antonia|Mazzali, Cristina|Iacovelli, Roberto|Maggi, Claudia|Gariboldi, Manuela|Pierotti, Marco Alessandro|Di Bartolomeo, Maria|Sottotetti, Elisa|Mennitto, Roberta|Bossi, Ilaria|de Braud, Filippo|Cleme
PMID: 25782327
144.
Journal: Oncology (Williston Park). 2015 Mar;29(3):175-83.
Title: Costs and effectiveness of genomic testing in the management of colorectal cancer.
Author: Goldstein, Daniel A|Shaib, Walid L|Flowers, Christopher R
PMID: 25783977
145.
Journal: Biomark Med. 2015;9(4):337-47.
Title: Personalized treatment for patients with colorectal cancer: role of biomarkers.
Author: Duffy, Michael J
PMID: 25808438
146.
Journal: Fundam Clin Pharmacol. 2015 Jun;29(3):219-37.
Title: UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.
Author: Etienne-Grimaldi, Marie-Christine|Boyer, Jean-Christophe|Thomas, Fabienne|Quaranta, Sylvie|Picard, Nicolas|Loriot, Marie-Anne|Narjoz, Celine|Poncet, Delphine|Gagnieu, Marie-Claude|Ged, Cecile|Broly, Franck|Le Morvan, Valerie|Bouquie, Regis|Gaub, Marie-Pie
PMID: 25817555
147.
Journal: Br J Cancer. 2015 May 12;112(10):1709-16.
Title: An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Author: Ichikawa, W|Uehara, K|Minamimura, K|Tanaka, C|Takii, Y|Miyauchi, H|Sadahiro, S|Fujita, K|Moriwaki, T|Nakamura, M|Takahashi, T|Tsuji, A|Shinozaki, K|Morita, S|Ando, Y|Okutani, Y|Sugihara, M|Sugiyama, T|Ohashi, Y|Sakata, Y
PMID: 25880011
148.
Journal: Gan To Kagaku Ryoho. 2015 May;42(5):585-9.
Title: [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
Author: Teruya, Tsuyoshi|Nakachi, Atsushi|Shimabukuro, Nobuhiro|Toritsuka, Daisuke|Azuma, Yasuharu|Hanashiro, Kiyotoshi|Nishiki, Takehiro|Ota, Morihito|Shimabuku, Masamori|Shiroma, Hiroshi
PMID: 25981652
149.
Journal: Vopr Onkol. 2015;61(2):266-9.
Title: [The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Author: Kit, O I|Vladimirova, L Yu|Vodolazhskiy, D I|Abramova, N A|Dvadnenko, K V
PMID: 26087609
150.
Journal: Rinsho Byori. 2015 Jul;63(7):870-5.
Title: [Companion Diagnostics Sub-Section of Anatomic Pathology Department in a Mid-Sized General Hospital: Start Up and Maintenance].
Author: Nakayama, Hirofumi|Yasuhara, Mayumi
PMID: 26591440
151.
Journal: J Clin Lab Anal. 2016 Jan;30(1):84-9.
Title: Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers.
Author: Sukasem, Chonlaphat|Atasilp, Chalirmporn|Chansriwong, Pichai|Chamnanphon, Montri|Puangpetch, Apichaya|Sirachainan, Ekapob
PMID: 25545261
152.
Journal: Acta Oncol. 2016;55(3):318-28.
Title: The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
Author: Butzke, Bettina|Oduncu, Fuat S|Severin, Franziska|Pfeufer, Arne|Heinemann, Volker|Giessen-Jung, Clemens|Stollenwerk, Bjorn|Rogowski, Wolf H
PMID: 26098842
153.
Journal: J Clin Pharmacol. 2016 Aug;56(8):966-73.
Title: Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
Author: Rudek, Michelle A|Dasari, Arvind|Laheru, Daniel|He, Ping|Jin, Runyan|Walker, Rosalind|Taylor, Gretchen E|Jimeno, Antonio|Donehower, Ross C|Hidalgo, Manuel|Messersmith, Wells A|Purcell, W Thomas
PMID: 26632033
154.
Journal: Int J Clin Oncol. 2016 Aug;21(4):696-703.
Title: UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Author: Miyata, Yoshinori|Touyama, Tetsuo|Kusumi, Takaya|Morita, Yoshitaka|Mizunuma, Nobuyuki|Taniguchi, Fumihiro|Manabe, Mitsuaki
PMID: 26710796
155.
Journal: Cell Mol Gastroenterol Hepatol. 2016 Jan;2(1):63-76.e5.
Title: Reduction of p53 by knockdown of the UGT1 locus in colon epithelial cells causes an increase in tumorigenesis.
Author: Liu, Miao|Chen, Shujuan|Yueh, Mei-Fei|Wang, Guangji|Hao, Haiping|Tukey, Robert H
PMID: 26807433
156.
Journal: Trials. 2016 Jan 25;17:46.
Title: Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Author: Yeh, Yung-Sung|Tsai, Hsiang-Lin|Huang, Ching-Wen|Wang, Jui-Ho|Lin, Yi-Wen|Tang, Hsiu-Chih|Sung, Yung-Chuan|Wu, Chang-Chieh|Lu, Chien-Yu|Wang, Jaw-Yuan
PMID: 26811156
157.
Journal: PLoS One. 2016 Jan 28;11(1):e0148081.
Title: Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
Author: Yi, Lang|Lin, Guigao|Zhang, Kuo|Wang, Lunan|Zhang, Rui|Xie, Jiehong|Li, Jinming
PMID: 26820647
158.
Journal: Drug Metab Pharmacokinet. 2016 Feb;31(1):90-94.
Title: Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Author: Atasilp, Chalirmporn|Chansriwong, Pichai|Sirachainan, Ekapob|Reungwetwattana, Thanyanan|Chamnanphon, Montri|Puangpetch, Apichaya|Wongwaisayawan, Sansanee|Sukasem, Chonlaphat
PMID: 26830078
159.
Journal: Exp Ther Med. 2016 Jan;11(1):201-207.
Title: Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: A case report and review of the literature.
Author: Lin, L I|Xu, Chun-Wei|Zhang, B O|Liu, Rong-Rui|Ge, Fei-Jiao|Zhao, Chuan-Hua|Jia, R U|Qin, Quan-Hong|Stojsic, Jelena|Wang, Yan|Xu, Jian-Ming
PMID: 26889240
160.
Journal: J Gastrointest Oncol. 2016 Apr;7(Suppl 1):S11-20.
Title: Molecular testing to optimize therapeutic decision making in advanced colorectal cancer.
Author: Semrad, Thomas J|Kim, Edward J
PMID: 27034809
161.
Journal: Clin Pharmacokinet. 2016 Sep;55(9):1145-57.
Title: Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.
Author: Mbatchi, Litaty Cephanoee|Robert, Jacques|Ychou, Marc|Boyer, Jean-Christophe|Del Rio, Maguy|Gassiot, Matthieu|Thomas, Fabienne|Tubiana, Nicole|Evrard, Alexandre
PMID: 27116457
162.
Journal: World J Gastroenterol. 2016 Apr 28;22(16):4250-8.
Title: Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Author: Yu, Qian-Qian|Qiu, Hong|Zhang, Ming-Sheng|Hu, Guang-Yuan|Liu, Bo|Huang, Liu|Liao, Xin|Li, Qian-Xia|Li, Zhi-Huan|Yuan, Xiang-Lin
PMID: 27122675
163.
Journal: Cancer Chemother Pharmacol. 2016 Jul;78(1):119-30.
Title: UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Author: Xu, Chunlei|Tang, Xushan|Qu, Yanli|Keyoumu, Saifuding|Zhou, Ning|Tang, Yong
PMID: 27220761
164.
Journal: Int J Clin Oncol. 2016 Aug;21(4):704.
Title: Erratum to: UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Author: Miyata, Yoshinori|Touyama, Tetsuo|Kusumi, Takaya|Morita, Yoshitaka|Mizunuma, Nobuyuki|Taniguchi, Fumihiro|Manabe, Mitsuaki
PMID: 27380166
165.
Journal: J Cancer Res Ther. 2016 Apr-Jun;12(2):782-6.
Title: DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients.
Author: Li, Guo-Yin|Duan, Jian-Feng|Li, Wan-Jun|Liu, Tao
PMID: 27461651
166.
Journal: Gan To Kagaku Ryoho. 2016 Nov;43(12):2468-2470.
Title: [A Case of Unresectable Advanced Rectal Cancer with a Pancreatic Tumor That Was Successfully Treated with FOLFIRINOX].
Author: Yabe, Nobushige|Murai, Shinji|Ozawa, Hiroki|Yokose, Takahiro|Oto, Ippei|Yoshikawa, Takahisa|Kitasato, Kenjiro|Shimizu, Hirotomo|Kojima, Kenji|Hasegawa, Hirotoshi|Kitagawa, Yuko
PMID: 28133357
167.
Journal: Mol Pharmacol. 2017 Mar;91(3):167-177.
Title: Cross-Talk between Alternatively Spliced UGT1A Isoforms and Colon Cancer Cell Metabolism.
Author: Audet-Delage, Yannick|Rouleau, Michele|Rouleau, Melanie|Roberge, Joannie|Miard, Stephanie|Picard, Frederic|Tetu, Bernard|Guillemette, Chantal
PMID: 28049773
168.
Journal: Oncologist. 2017 Mar;22(3):293-303.
Title: Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Author: Kim, Ji-Won|Lee, Keun-Wook|Kim, Kyu-Pyo|Lee, Ju Hyun|Hong, Yong Sang|Kim, Jeong-Eun|Kim, Sun Young|Park, Sook Ryun|Nam, Byung-Ho|Cho, Sang-Hee|Chung, Ik-Joo|Park, Young Suk|Oh, Ho-Suk|Lee, Myung-Ah|Kang, Hye Jin|Park, Young Iee|Song, Eun-Kee|Han, Hye Sook
PMID: 28209749
169.
Journal: Onco Targets Ther. 2017 Jun 19;10:3071-3081.
Title: Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.
Author: Bai, Yu|Wu, Hai-Wei|Ma, Xu|Liu, Ying|Zhang, Yan-Hua
PMID: 28790841
170.
Journal: Clin Lab. 2017 Sep 1;63(9):1339-1346.
Title: UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Author: Peng, Hongwei|Duan, Zhouping|Pan, Decheng|Wen, Jinhua|Wei, Xiaohua
PMID: 28879724
171.
Journal: Asian Pac J Cancer Prev. 2017 Oct 26;18(10):2803-2807.
Title: Prediction of Response to Irinotecan and Drug Toxicity Based on Pharmacogenomics Test: A Prospective Case Study in Advanced Colorectal Cancer
Author: Emami, A H|Sadighi, S|Shirkoohi, R|Mohagheghi, M A
PMID: 29072417
172.
Journal: World J Gastroenterol. 2017 Oct 7;23(37):6854-6867.
Title: Association of insertion-deletions polymorphisms with colorectal cancer risk and clinical features.
Author: Marques, Diego|Ferreira-Costa, Layse Raynara|Ferreira-Costa, Lorenna Larissa|Correa, Romualdo da Silva|Borges, Aline Maciel Pinheiro|Ito, Fernanda Ribeiro|Ramos, Carlos Cesar de Oliveira|Bortolin, Raul Hernandes|Luchessi, Andre Ducati|Ribeiro-Dos-Santos,
PMID: 29085228
173.
Journal: Radiother Oncol. 2017 Dec 19. pii: S0167-8140(17)32749-4.
Title: Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.
Author: Zhu, Ji|Li, Xinxiang|Shen, Yunzhu|Guan, Yun|Gu, Weilie|Lian, Peng|Sheng, Weiqi|Cai, Sanjun|Zhang, Zhen
PMID: 29273261
174.
Journal: World J Gastroenterol. 2017 Dec 28;23(48):8533-8543.
Title: Analysis of 12 variants in the development of gastric and colorectal cancers.
Author: Cavalcante, Giovanna C|Amador, Marcos At|Ribeiro Dos Santos, Andre M|Carvalho, Darlen C|Andrade, Roberta B|Pereira, Esdras Eb|Fernandes, Marianne R|Costa, Danielle F|Santos, Ney Pc|Assumpcao, Paulo P|Ribeiro Dos Santos, Andrea|Santos, Sidney
PMID: 29358861
175.
Journal: Toxicol Sci. 2018 Jul 1;164(1):205-217.
Title: Structure-Dependent Modulation of Aryl Hydrocarbon Receptor-Mediated Activities by Flavonoids.
Author: Jin, Un-Ho|Park, Hyejin|Li, Xi|Davidson, Laurie A|Allred, Clinton|Patil, Bhimanagouda|Jayaprakasha, Guddadarangavva|Orr, Asuka A|Mao, Leevin|Chapkin, Robert S|Jayaraman, Arul|Tamamis, Phanourios|Safe, Stephen
PMID: 29584932
176.
Journal: Methods Mol Biol. 2018;1765:281-297.
Title: Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Author: Lin, Patrick S|Semrad, Thomas J
PMID: 29589315
177.
Journal: Pharmacol Rep. 2018 Jun;70(3):470-475.
Title: Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems.
Author: Bejrowska, Anna|Pawlowska, Monika|Mroz, Anna|Mazerska, Zofia
PMID: 29649683
178.
Journal: Cancer Chemother Pharmacol. 2018 Jul;82(1):87-98.
Title: UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
Author: Yu, Qianqian|Zhang, Tao|Xie, Conghua|Qiu, Hong|Liu, Bo|Huang, Liu|Peng, Ping|Feng, Jueping|Chen, Jigui|Zang, Aihua|Yuan, Xianglin
PMID: 29728798
179.
Journal: Eur J Cancer. 2018 Aug;99:66-77.
Title: Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Author: Tejpar, Sabine|Yan, Pu|Piessevaux, Hubert|Dietrich, Daniel|Brauchli, Peter|Klingbiel, Dirk|Fiocca, Roberto|Delorenzi, Mauro|Bosman, Fred|Roth, Arnaud D
PMID: 29909091
180.
Journal: Drug Resist Updat. 2018 Jul;39:18-40.
Title: Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Author: Cecchin, Erika|De Mattia, Elena|Ecca, Fabrizio|Toffoli, Giuseppe
PMID: 30075835
181.
Journal: Pharmacol Res. 2018 Sep 11;136:133-139.
Title: Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.
Author: Salvador-Martin, Sara|Garcia-Gonzalez, Xandra|Garcia, Maria I|Blanco, Carolina|Garcia-Alfonso, Pilar|Robles, Luis|Gravalos, Cristina|Pachon, Vanessa|Longo, Federico|Martinez, Virginia|Sanjurjo-Saez, Maria|Lopez-Fernandez, Luis A
PMID: 30213564
182.
Journal: Cancer Sci. 2018 Sep 23.
Title: UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.
Author: Kimura, Kei|Yamano, Tomoki|Igeta, Masataka|Imada, Ayako|Jihyung, Song|Babaya, Akihito|Hamanaka, Michiko|Kobayashi, Masayoshi|Tsukamoto, Kiyoshi|Noda, Masafumi|Ikeda, Masataka|Tomita, Naohiro
PMID: 30246377
183.
Journal: Cancer Chemother Pharmacol. 2018 Oct 4. pii: 10.1007/s00280-018-3693-6.
Title: A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients.
Author: Hamaguchi, Tetsuya|Tsuji, Akihito|Yamaguchi, Kensei|Takeda, Koji|Uetake, Hiroyuki|Esaki, Taito|Amagai, Kenji|Sakai, Daisuke|Baba, Hideo|Kimura, Masami|Matsumura, Yasuhiro|Tsukamoto, Tetsuji
PMID: 30284603
184.
Journal: Clin Pharmacol Ther. 2018 Oct 19.
Title: The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice.
Author: Toffoli, Giuseppe|Innocenti, Federico|Polesel, Jerry|De Mattia, Elena|Sartor, Franca|Fratte, Chiara Dalle|Ecca, Fabrizio|Dreussi, Eva|Palazzari, Elisa|Guardascione, Michela|Buonadonna, Angela|Foltran, Luisa|Garziera, Marica|Bignucolo, Alessia|Nobili, Stef
PMID: 30339275
185.
Journal: Cancer Chemother Pharmacol. 2018 Oct 30. pii: 10.1007/s00280-018-3711-8.
Title: Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
Author: Fujii, Hironori|Yamada, Yunami|Watanabe, Daichi|Matsuhashi, Nobuhisa|Takahashi, Takao|Yoshida, Kazuhiro|Suzuki, Akio
PMID: 30377777